PEN Strangle Strategy

PEN (Penumbra, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors.

PEN (Penumbra, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $12.45B, a trailing P/E of 72.70, a beta of 0.70 versus the broader market, a 52-week range of 221.26-362.41, average daily share volume of 488K, a public-listing history dating back to 2015, approximately 5K full-time employees. These structural characteristics shape how PEN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.70 indicates PEN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 72.70 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a strangle on PEN?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current PEN snapshot

As of June 25, 2026, spot at $316.50, ATM IV 43.30%, IV rank 8.51%, expected move 12.41%. The strangle on PEN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this strangle structure on PEN specifically: PEN IV at 43.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a PEN strangle, with a market-implied 1-standard-deviation move of approximately 12.41% (roughly $39.29 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PEN expiries trade a higher absolute premium for lower per-day decay. Position sizing on PEN should anchor to the underlying notional of $316.50 per share and to the trader's directional view on PEN stock.

PEN strangle setup

The PEN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PEN near $316.50, the first option leg uses a $330.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PEN chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PEN shares for the stock leg in covered calls and collars).

PEN strangle risk and reward

Net Premium / Debit

-$1,772.00

Max Profit (per contract)

Unbounded

Max Loss (per contract)

-$1,772.00

Breakeven(s)

$282.28, $347.72

Risk / Reward Ratio

Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

PEN strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on PEN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on PEN

Strangles on PEN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PEN chain.

PEN thesis for this strangle

The market-implied 1-standard-deviation range for PEN extends from approximately $277.21 on the downside to $355.79 on the upside. A PEN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current PEN IV rank near 8.51% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PEN at 43.30%. As a Healthcare name, PEN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PEN-specific events.

PEN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PEN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PEN alongside the broader basket even when PEN-specific fundamentals are unchanged. Always rebuild the position from current PEN chain quotes before placing a trade.

Frequently asked questions

What is a strangle on PEN?

A strangle on PEN is the strangle strategy applied to PEN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With PEN stock trading near $316.50, the strikes shown on this page are snapped to the nearest listed PEN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.

How are PEN strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PEN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 43.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,772.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a PEN strangle?

The breakeven for the PEN strangle priced on this page is roughly $282.28 and $347.72 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PEN market-implied 1-standard-deviation expected move is approximately 12.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

When should you consider a strangle on PEN?

Strangles on PEN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PEN chain.

How does current PEN implied volatility affect this strangle?

PEN ATM IV is at 43.30% with IV rank near 8.51%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related PEN analysis

• Strangle strategy reference
• PEN options overview
• PEN P&L curve (full chain)
• PEN options chain
• PEN volatility skew